Kalytera Therapeutics, Inc. announced the appointment of Andrew L. Salzman, M.D. as Kalytera's Chief Medical Officer. In this role, Dr. Salzman will lead efforts to advance Kalytera's drug candidates into human clinical studies. Dr. Salzman is a renowned physician, inventor, and biomedical entrepreneur who has brought numerous medicines from conception to clinical trials.